Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Inhibitor Therapeutics, Inc. (INTI : OTC)
 
 • Company Description   
Inhibitor Therapeutics Inc. is a pharmaceutical development company. It discovers, develops and plans to commercialize therapeutics for cancerous and non-cancerous proliferation disorders. The company's lead product consists of SUBA-Itraconazole, a patented, oral formulation of the currently marketed, well-understood, anti-fungal drug, Itraconazole, for treatment of prostate and lung cancers, which are in clinical stage. Inhibitor Therapeutics Inc., formerly known as HedgePath Pharmaceuticals Inc., is based in Tampa, United States.

Number of Employees: 9

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.05 Daily Weekly Monthly
20 Day Moving Average: 2,687 shares
Shares Outstanding: 172.57 (millions)
Market Capitalization: $8.63 (millions)
Beta: -0.59
52 Week High: $0.10
52 Week Low: $0.03
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 3.09% -0.77%
12 Week 25.00% 5.14%
Year To Date -16.81% -22.09%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
3014 W. Palmira AvenueSuite 302
-
Tampa,FL 33629
USA		 ph: 813-864-2562
fax: 813-527-0500		 stilman@tiberend.com http://www.inhibitortx.com
 
 • General Corporate Information   
Officers
Francis E. O'Donnell - Executive Chairman of the Board and Chief Executiv
James A. McNulty - Interim Chief Financial Officer; Treasurer and Sec
Samuel J. Sears - Director
Niraj Vasisht - Director
Michelle Yanez - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 45720M105
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/05/25
Share - Related Items
Shares Outstanding: 172.57
Most Recent Split Date: (:1)
Beta: -0.59
Market Capitalization: $8.63 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/05/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: 100.00%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -120.86
12/31/24 - -94.30
ROA
06/30/25 - -
03/31/25 - -55.21
12/31/24 - -49.28
Current Ratio
06/30/25 - -
03/31/25 - 46.68
12/31/24 - 8.02
Quick Ratio
06/30/25 - -
03/31/25 - 46.68
12/31/24 - 8.02
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Book Value
06/30/25 - -
03/31/25 - 0.01
12/31/24 - 0.01
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©